Company

Voyager Therapeutics

Voyager Therapeutics develops gene therapies for neurological diseases, including Alzheimer's and Parkinson's, from Cambridge, US.

About

Founded in 2014 and based in Cambridge, US, Voyager Therapeutics develops genetic medicines for neurological disorders using its TRACER AAV capsid platform. Its lead program, VY7523 for Alzheimer's disease, is in clinical development. The company completed an IPO on November 10, 2015 and has raised USD 70 mn in total. Al Sandrock is the CEO.

2Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in